• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Interleukin-23 autoantibodies linked to severe opportunistic infections

byJunghoon KoandKiera Liblik
April 3, 2024
in Chronic Disease, Infectious Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this cohort study, neutralizing autoantibodies against interleukin-23 (anti-IL-23) were associated with severe, persistent opportunistic infections in patients with invasive bacterial, mycobacterial, and fungal infections.

2. Among a cohort of patients with thymoma, anti-IL-23 was associated with higher infection status.

Evidence Rating Level: 2 (Good)

Study Rundown: Anti-cytokine antibodies are increasingly recognized in immunodeficiency and severe infectious conditions. IL-23 and interleukin-12 (IL-12), whose structures share a common protein subunit (p40), are two cytokines that both engage the IL-12Rβ1 receptor and are essential for the production of interferon-γ. However, unlike IL-12, IL-23 is essential in controlling inflammation in various skin, lungs, gastrointestinal tract, and brain tissues. It is secreted by dendritic cells and macrophages in response to mycobacteria and fungi. Interestingly, patients with thymoma, in whom anti-IL-12 is commonly found, have exhibited a low incidence of opportunistic infections. Moreover, anti-IL-23 has been described as a cross-reactive phenomenon in thymoma patients who exhibit anti-IL-12. This prompted a series of cohort studies that investigated the presence of anti-IL-23 in patients who had the presence of anti-IL-12 (discovery cohort), thymoma (validation cohort), and infections similar to those seen in thymoma (expansion cohort). Overall, neutralizing anti-IL-23 was associated with more severe, persistent opportunistic infections among patients with invasive, mycobacterial, and fungal infections. In addition, in the validation cohort of patients with thymoma, anti-IL-23 was associated with higher infection status. The generalizability of the study findings is limited, given that patients were recruited based on underlying conditions or infections.

Click to read the study in NEJM

In-Depth [retrospective cohort]: This series of retrospective cohort studies aimed to investigate the role of anti-IL-23 with respect to opportunistic infection. From 2007 to 2021, multiple groups of patients (discovery, validation, and expansion cohorts) were evaluated for the presence anti-IL-23 using blood samples from the National Institutes of Health. In the discovery cohort, 30 patients with anti-IL-12 and 30 healthy controls were tested for anti-IL-23. Among the patients with anti-IL-12, 23 patients (77%) had binding activity to anti-IL-23, and 15 patients (50%) had neutralizing activity against IL-23-induced signal transducer and activator of transcription 3 (STAT3) phosphorylation, responsible for the maturation of various immune system cells. The degree of neutralization by anti-IL-23 was correlated to the severity of infection. In the validation cohort, 91 patients with thymoma, in whom anti-IL-12 is often detected, were evaluated for the presence of anti-IL-23. Of these patients, 24 (26%) had IL-23 binding activity, and 17 (19%) had neutralizing activity against IL-23-induced STAT3 phosphorylation. In total, 10 of the 17 patients with neutralizing anti-IL-23 had opportunistic infections. Moreover, 64 patients without neutralizing anti-IL-23 activity did not have infections. In the expansion cohort, 128 patients with other severe intracellular infections (without anti-IL-12 or thymoma) were evaluated for anti-IL-23 to determine its role in uncommon infection presentations. In addition, anti-IL-23 binding activity was detected in 6 of 32 patients (19%) with severe intracellular infections, 2 of 16 patients (12%) with unusual intracranial infections, and 3 of 30 patients (10%) with invasive mold infections. These cohort studies demonstrate that neutralizing anti-IL-23 is associated with severe opportunistic infections.

RELATED REPORTS

Food compounds associated with disease activity in inflammatory bowel disease 

2 Minute Medicine Rewind June 23, 2025

Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chronic diseaseinfectious diseaseInterleukin-23 autoantibodiesOpportunistic infectionsthymoma
Previous Post

#VisualAbstract: Cervical intraepithelial neoplasia grade 2 and risk of preterm birth

Next Post

Novel lateral flow assay effective for point-of-care detection of Neisseria gonorrhea in symptomatic patients

RelatedReports

Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Food compounds associated with disease activity in inflammatory bowel disease 

June 25, 2025
Weekly Rewinds

2 Minute Medicine Rewind June 23, 2025

June 23, 2025
Lisinopril and carvedilol reduce cardiotoxicity in breast cancer patients receiving trastuzumab and anthracyclines
Cardiology

Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms

June 19, 2025
Survival greater in cervical cancer patients undergoing abdominal hysterectomy compared to minimally invasive techniques: the LACC trial
Weekly Rewinds

2 Minute Medicine Rewind June 16, 2025

June 16, 2025
Next Post
New female condoms demonstrate efficacy

Novel lateral flow assay effective for point-of-care detection of Neisseria gonorrhea in symptomatic patients

Low vitamin D levels accelerates muscle mass loss in patients with chronic liver disease

Shared decision-making tool for antidepressants improves patient and physician satisfaction

Wellness Check: Mental Health

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
  • Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.